Xuening Yang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.
Journal: Signal transduction and targeted therapy
Published: October 13, 2025
Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up.
Journal: Chinese medical journal
Published: February 04, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers.
Journal: Med (New York, N.Y.)
Published: December 28, 2024
Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression.
Journal: BMC medicine
Published: June 17, 2024
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial.
Journal: Cancer cell
Published: January 07, 2024
Parameterized Gompertz-Guided Morphological AutoEncoder for Predicting Pulmonary Nodule Growth.
Journal: IEEE transactions on medical imaging
Published: July 20, 2023
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology.
Journal: Cancer biology & medicine
Published: May 24, 2019
TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer.
Journal: Translational lung cancer research
Published: May 21, 2019
Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: March 29, 2018
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
Journal: Journal of hematology & oncology
Published: March 02, 2015
Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma
Journal: Zhonghua yi xue za zhi
Published: November 18, 2014
Last Updated: 09/26/2026